
Shanghai Henlius Biotech Investor Relations Material
Latest events

H2 2024
24 Mar, 2025

H1 2024
25 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Shanghai Henlius Biotech Inc
Access all reports
Shanghai Henlius Biotech Inc is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of biologic drugs, particularly biosimilars and monoclonal antibody therapies. The company’s product portfolio addresses a range of therapeutic areas, including oncology, autoimmune diseases, and infectious diseases. Henlius operates advanced manufacturing facilities and research centers, employing innovative biotechnology to support its drug development pipeline and expand access to biologic treatments. The company is headquartered in Shanghai, China, and its shares are listed on the HKEX.
Key slides for Shanghai Henlius Biotech Inc


H2 2024
Shanghai Henlius Biotech Inc


H2 2024
Shanghai Henlius Biotech Inc
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
2696
Country
🇭🇰 Hong Kong